Fulgent Genetics Announces Full Abstract Publication of FID-007 Combination Therapy in Head and Neck Cancer at ASCO 2026 Fulgent Genetics, a technology-driven life sciences company with established laboratory services and an expanding therapeutic development division, announced that the full abstract…
Natera to Present 35 Studies at ASCO 2026, Highlighting Expanding Leadership in Oncology and MRD-Guided Cancer Care Natera, a global leader in cell-free DNA and precision medicine, announced a landmark oncology data program for the 2026 American Society of Clinical…
Veracyte to Present Landmark OPTIMA and ENZAMET Trial Data at ASCO 2026, Strengthening Evidence for Genomic Testing in Breast and Prostate Cancer Care Veracyte, a leading cancer diagnostics company, has announced that new data from two major Phase III clinical…
AstraZeneca to Showcase Broad Oncology and Rare Disease Pipeline at ASCO 2026 with Late-Breaking Data Across Liver, Breast, Bladder Cancers and Amyloidosis AstraZeneca will present a comprehensive slate of late-breaking and oral presentations at the American Society of Clinical Oncology…
Future Health Challenge Awards USD 300,000 to Global Innovators Advancing Early Detection and Population Health Sensing at World Health Assembly Global health innovation took center stage in Geneva as the inaugural Future Health Challenge 2026: Building Anticipatory Health Systems through…
Enhertu® Recommended for EU Approval by CHMP for Treatment of Previously Treated HER2-Positive Metastatic Solid Tumors Enhertu® (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate (ADC), has received a positive recommendation for approval in the European Union for the treatment of…
ClearNote Health to Present New Multi-Cohort Validation Data for Avantect® Pancreatic Cancer Test at 2026 ASCO Annual Meeting ClearNote Health, a company focused on advancing early detection technologies for some of the most lethal cancers, announced that it will present…
Datroway® Receives U.S. FDA Approval as First TROP2-Directed Antibody Drug Conjugate for First-Line Treatment of Metastatic Triple-Negative Breast Cancer in Patients Not Eligible for PD-1/PD-L1 Inhibitor Therapy Daiichi Sankyo and AstraZeneca announced that Datroway (datopotamab deruxtecan-dlnk) has received approval in…
HealthNet and AndHealth Open New Pharmacy in Indianapolis to Expand Affordable Medication Access and Integrated Specialty Care HealthNet and AndHealth have officially opened the new HealthNet Pharmacy at the Barrington Health & Dental Center on Indianapolis’ east side, marking a…
FDA Approves Gilead’s Hepcludex, Marking a Breakthrough for Patients Living With Chronic Hepatitis Delta The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Hepcludex® (bulevirtide-gmod) 8.5 mg, developed by Gilead Sciences, for the treatment of adults living…
Accendra Health Launches Comprehensive Debt Exchange and Refinancing Initiative Accendra Health, has initiated a broad debt restructuring transaction designed to strengthen its balance sheet, extend debt maturities, and secure new capital through a combination of exchange offers, consent solicitations, and…
Virta Health Provides Update on Security Incident and Ongoing Efforts to Protect Personal Information Virta Health Corp. and Virta Medical PC (collectively referred to as “Virta Health”), a leader in technology-enabled healthcare services, has issued a substitute notice regarding a…